Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri (Q36954152)
Jump to navigation
Jump to search
scientific article published on 16 September 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri |
scientific article published on 16 September 2015 |
Statements
1 reference
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri (English)
1 reference
1 reference
human papillomavirus
29 September 2024
Kate E Broderick
1 reference
David B Weiner
1 reference
Cornelia L Trimble
1 reference
Matthew P Morrow
1 reference
Kimberly A Kraynyak
1 reference
Xuefei Shen
1 reference
Michael Dallas
1 reference
Jian Yan
1 reference
Lance Edwards
1 reference
R Lamar Parker
1 reference
Lynette Denny
1 reference
Mary Giffear
1 reference
Ami Shah Brown
1 reference
Kathleen Marcozzi-Pierce
1 reference
Divya Shah
1 reference
Anna M Slager
1 reference
Albert J Sylvester
1 reference
Amir Khan
1 reference
Robert J Juba
1 reference
Timothy A Herring
1 reference
Jean Boyer
1 reference
Jessica Lee
1 reference
Niranjan Y Sardesai
1 reference
Mark L Bagarazzi
1 reference
16 September 2015
1 reference
1 reference
10008
1 reference
2078-2088
1 reference
Identifiers
1 reference
1 reference
1 reference